

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

May 19, 2005 Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1623

NANDI ET AL.

Examiner: Michael C. Henry

APPLICATION NO: 10/631,874

FILED: JULY 31, 2003

FOR: FEXOFEDADINE COMPOSITION AND PROCESS FOR

PREPARING

MS: Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed June 24, 2004. Since it is being filed in accordance with 37 C.F.R. §1.97(c), a letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

These references were cited in a search report in a corresponding International application. Copies of these references and the search report are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-7945

Date: May 19, 2005

05/23/2005 SSESHE1 00000032 190134 10631874

01 FC:1806

180.00 DA

John D. Thallemer Attorney for Applicants

Reg. No. 34,940



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 4850229/5 US

Express Mail Label Number

May 19 2005 Bate of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1623

NANDI ET AL.

Examiner: Michael C. Henry

APPLICATION NO: 10/631,874

FILED: JULY 31, 2003

FOR: FEXOFEDADINE COMPOSITION AND PROCESS FOR

PREPARING

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080

(862) 778-7945

Date: May 19, 2005

John D. Thallemer Attorney for Applicants Reg. No. 34,940 **FORM PTO-1449** (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. RG/G-33302P1 APPLICATION NO. 10/631,874 **APPLICANT** NANDI ET AL **FILING DATE** JULY 31, 2003

Group 1623

MAY 1 9 2005

U.S. PATENT DOCUMENTS EXAMINER | **CLASS SUBCLASS FILING DATE DOCUMENT NUMBER** DATE NAME INITIAL AA AB AC AD AE AF AG AH Αl AJ AK AL FOREIGN PATENT DOCUMENTS TRANSLATION **DOCUMENT NUMBER CLASS SUBCLASS** DATE **OFFICE** YES NO 12/9/97 **AM** 09 315971 JP (Abstract) 11/22/00 AN 1 054 019 EP 7/6/00 wo 00/38650 AO AP 03/041683 5/22/03 WO AQ OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.) Database WPI, Section Ch, Week 199808, Derwent Publications, Ltd., London, GB; Class A96, AN 1998-082557 XP002305733 and JP 09 315971 (1997). AR Graul et al., "Fexofenadine Hydrochloride Antihistaminic Terfenadine Carboxylate Hydrochloride MDL-16455A Allegra™", Drugs of the Future, Vol. 21, No. 10, pp. 1017-1021 (1996). AS Patent Abstracts of Japan, Vol. 1998, No. 12 and JP 10 194969 (1998). AT Database WPI, Section Ch, Week 198623, Derwent Publications Ltd., London, GB; Class B03, AN 1986-147747 XP 002305734 and JP 61 083123 (1986). AU **DATE CONSIDERED**

*EXAMINER:

EXAMINER

Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.